Affiliation:
1. Department of Oncology, Jiangnan Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine (Xiaoshan Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China
Abstract
This study aimed to develop a DNA methylation-based nomogram for predicting biochemical recurrence in patients with prostate cancer. A DNA methylation signature was obtained via univariate, lasso, and stepwise multivariate Cox regression models. A 11-DNA methylation signature yielded a high evaluative performance for biochemical-recurrence-free survival. Cox regression analysis indicated that 11-DNA methylation signature and Gleason score served as independent risk factors. A nomogram was constructed based on the 11-DNA methylation signature and Gleason score, and C-index as well as the calibration plots demonstrated good performance and clinical application of the nomogram. A DNA methylation-associated nomogram serve as a prognosis stratification tool to predict the biochemical recurrence of prostate cancer patients after radical prostatectomy.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference33 articles.
1. Cancer statistics, 2020;Siegel;CA.,2020
2. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent;Mottet;Eur Urol,2017
3. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options;Sanda;J Urol,2018
4. Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy;Liesenfeld;J Urol,2017
5. Prostate specific antigen testing after radical prostatectomy-can we stop at 20 years?;Ludwig;J Urol,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献